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18F-Fluorodeoxyglucose PET/CT in a
Patient with Esophageal and Genital
Leiomyomatosis 
Diffuse esophageal leiomyomatosis is a rare benign tumor, which can be asso-
ciated with leiomyoma in female genital tracts involving the uterus, vagina, and
vulva. Alport syndrome, an inherited disorder that includes the kidneys, eyes, and
sensorineural hearing loss, is also rarely associated with these multiple leiomy-
omatosis. In our case, 
18F-fluoroseoxyglucose positron emission tomography/
computed tomography was used to distinguish esophageal and genital leiomy-
omatosis from malignant masses.
iffuse esophageal leiomyomatosis is a rare benign disease of proliferating
smooth muscle that can be accompanied by leiomyoma of extrae-
sophageal organs including the tracheobronchial and genital tracts (1-3).
Moreover, diffuse leiomyomatosis can be associated with Alport syndrome in familial
cases (2, 4). 
18F-fluoroseoxyglucose positron emission tomography (
18F-FDG-PET) can
be useful in diagnosis since the benign masses can form lesions in the esophagus and
extraesophageal organs that may be confused with malignancy. However, few reports
have been published on the use of 
18F-FDG PET in diffuse leiomyomatosis involving
multiple organs. We describe 
18F-FDG PET/computed tomography (CT) findings in a
patient with esophageal and genital leiomyomatosis.
CASE REPORT
A 49-year-old woman was hospitalized for further evaluation of dysphagia.
Esophagoscopy revealed a huge mass in the lower esophageal portion. Abdominal CT
examination demonstrated a huge low-attenuated submucosal mass in the esophagus.
Additional heterogeneous highly-attenuated masses were evident in the uterus and
vulvar region. While diagnosis of gastrointestinal stromal tumor or leiomyoma is
typical from such CT observations, preferred according to conventional CT, a
malignancy cannot be fully excluded. Appropriately, the patient was referred to the
nuclear medicine department for 
18F-FDG PET/CT to differentiate the esophageal and
genital masses as malignant or benign. After a 6 hours fast, the patient was
intravenously administered 370 MBq 
18F-FDG. At the time of injection, serum glucose
level was 97 mg/dl. The patient was instructed to rest comfortably for 60 min while
whole body PET/CT images were obtained using a Gemini Dual PET/CT scanner
(Philips Medical Systems, Amsterdam, The Netherlands). Seven frames (2.5
min/frame) of emission PET data were acquired in a three-dimensional (3D) mode
after non-contrast CT scans from the base of the skull to the upper thigh (tube rotation
time of 1 second per revolution, 120 kV, 50 mA, 6.5 mm per rotation, and acquisition
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Fig. 1. Esophageal and genital leiomy-
omatosis 
A. Huge abnormal increased 
18F-FDG
uptake lesion (arrows) in esophagus
(maximal SUV: 3.8) noted on PET/CT
image (upper row). Corresponding
contrast enhanced CT images
demonstrate abnormal mass lesions in
each organ.
B. Hypermetabolic lesions (arrows) were
evident in pelvic region including uterus
(maximal SUV: 6.13) (middle row).
C. Hypermetabolic lesions (arrows) were
evident in vulvar region (maximal SUV:
2.81) (lower row).
D. Arrows point to lesions evident in on
PET.
E-J. Pathologic examination. Grossly, 13
cm (length)×8 cm (width)×6 cm (depth)
poorly circumscribed, sausage-like,
white/pink, firm muscular mass oriented
across distal esophagus and gastric
cardia was evident. Diffusely thickened
esophageal wall measured 2 cm in
maximal thickness (E). Histologically,
Hematoxylin & Eosin staining (×40 in
panel F, ×200 in panel G) reveals
characteristics of leiomyoma. Multiple
confluent well-differentiated smooth
muscle proliferations were evident. Cells
formed fascicles and interlacing bundles
without cytologic atypia. Immunostaining
for smooth-muscle actin (×40) was
strongly positive in smooth-muscle origin
tumor cells with control reaction of
microvillous projections in apical cell
membrane (H). Uterus lesion also
demonstrates as leiomyoma pattern in
Hematoxylin & Eosin staining (×100 in
panel I, ×400 in panel J).
E F
GH
IJreconstructed with non-contrast CT using 3D-Row-Action
Maximum-Likelihood Algorithm reconstruction (field of
view = 576 mm, slice thickness = 4 mm, matrix size = 144
×144, voxel size = 4.5×4.5×4 mm). Standardized
uptake value (SUV) was calculated based on the injected
dose and patient body weight. PET/CT demonstrated
intensely increased 
18F-FDG uptake with 3.8 of maximal
SUV in the esophagus, 6.13 in the uterus, and 2.81 in the
vulvar mass (Fig. 1A-D), which was indicative of high
probabilities of malignancy. Each mass was excised.
Pathological testing confirmed that each mass was benign
leiomyomatosis (Fig. 1E-J). The patient’s son was remark-
able for Alport syndrome, and had undergone removal of
an esophageal leiomyomatosis nine years previously.
However, the patient showed no specific abnormal sign of
Alport syndrome.
DISCUSSION
Leiomyoma in the esophagus must be differentiated from
malignant esophageal carcinoma, cyst, or bulbous stricture.
Rarely, thickened layers of the esophageal wall can also be
caused by diffuse leiomyomatosis, a benign muscular
abnormality (1). Diffuse leiomyomatosis is also known as
giant muscular hypertrophy with diffuse proliferation of
the esophageal smooth muscle. The large tumor formation
predominantly occurs in the middle and distal third of the
esophagus. The most common clinical symptoms are
dysphasia, vomiting, and retrosternal pain due to luminal
narrowing and motor disorder of esophagus. These leiomy-
omatosis frequently involve extraesophageal organs such
as tracheobronchial tree or female genital tract (uterus,
vagina, vulva, and clitoris) and also show hyperplasia of
the thoracic or genital smooth muscles (2, 3). The familiar
form of leiomyomatosis can be associated with Alport
syndrome, a hereditary disease that displays hematuric
nephropathy and sensorial deficiencies including
sensorineural hearing loss and congenital cataracts. It is
transmitted as a X-linked dominant and may affect females
without sign of nephropathy, which is revealed as Alport
syndrome carrier status (4-7). This was presently the case.
Previous reports have described increased 
18F-FDG uptake
in leiomyomas (8-11). Leiomyoma with intense 
18F-FDG
accumulation can be confused with a malignant lesion. The
cause of hypermetabolism of this benign condition is
probably due to higher levels of growth factors and
increased peristaltic activity in smooth muscles (3, 8-11).
Approximately 10% of leiomyomas in pre-manopausal
women display focal 
18F-FDG uptake (maximal SUV > 3.0)
(12). In fact, malignant tumors cannot be distinguished
from hypermetabolic benign leiomyomas using 
18F-FDG
PET. Thus, leiomyomatosis of multiple organs may be a
cause of false-positive PET and represents a pitfall for
correct diagnosis between benign and malignant lesions.
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